May 15, 2019
Powles T et al. Nature Medicine 2019;25:1706–1714.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
You might also be interested by
Posters
Development of a Pathologist Scoring Method to Determine Inflamed, Excluded or Desert Immune Phenotype in Carcinoma
March 5, 2025
Histopathology
More infoScientific Publications
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
January 27, 2025
Histopathology
More infoPosters
Development of a visual scoring method to determine inflamed, excluded or desert immune phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer, and Urothelial Cancer
November 7, 2024
Histopathology
More infoBrochures & Infographics
Immunohistochemistry (IHC) Biomarker List
October 10, 2024
Histopathology
More info